This is a working overview of incretin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
The diminished Byzantine state survived for another century through diplomacy and favourable external developments. The Ottomans gradually subjugated Anatolia and simultaneously expanded into Europe from 1354, taking Philippopolis in 1363, Adrianopolis in 1369, and Thessalonica in 1387. Dynastic struggles increasingly depended on Venetian, Genoese, and Ottoman backing. After Manuel II (r. 1391–1425) refused to pay homage to Sultan Bayezid I in 1394, Constantinople was besieged until the rampaging warlord Timur decisively defeated Bayezid in 1402, with the city perilously close to surrender. After Ankara, Manuel II gained nearly two decades of relative peace as Ottoman succession struggles and later Anatolian campaigns occupied the sultans. In 1421, his unsuccessful backing of the claimant Mustafa Çelebi led to a renewed Ottoman assault. Although John VIII (r. 1425–1448) reconciled with the Catholic West at the Council of Florence, his empire steadily diminished. In 1452, Sultan Mehmed II resolved to capture Constantinople, and laid siege early the following year. On 29 May 1453, the city was captured, the last emperor, Constantine XI, died in battle, and the Byzantine Empire ended.
== Discovery and nomenclature == The antigen Thy-1 was the first T cell marker to be identified. Thy-1 was discovered by Reif and Allen in 1964 during a search for heterologous antisera against mouse leukemia cells, and was demonstrated by them to be present on murine thymocytes, on T lymphocytes, and on neuronal cells. It was originally named theta (θ) antigen, then Thy-1 (THYmocyte differentiation antigen 1) due to its prior identification in thymocytes (precursors of T cells in the thymus). The human homolog was isolated in 1980 as a 25kDa protein (p25) of T-lymphoblastoid cell line MOLT-3 binding with anti-monkey-thymocyte antisera. The discovery of Thy-1 in mice and humans led to the subsequent discovery of many other T cell markers, which is very significant to the field of immunology since T cells (along with B cells) are the major cellular components of the adaptive immune response.
== Regulation == The activity of cysteine proteases is regulated by a few general mechanisms, which includes the production of zymogens, selective expression, pH modification, cellular compartmentalization, and regulation of their enzymatic activity by endogenous inhibitors, which seemingly is the most efficient mechanism associated with the regulation of the activity of cysteine proteases. Proteases are usually synthesized as large precursor proteins called zymogens, such as the serine protease precursors trypsinogen and chymotrypsinogen, and the aspartic protease precursor pepsinogen. The protease is activated by removal of an inhibitory segment or protein. Activation occurs once the protease is delivered to a specific intracellular compartment (for example the lysosome) or extracellular environment (for example the stomach). This system prevents the cell that produces the protease from being damaged by it. Protease inhibitors are usually proteins with domains that enter or block a protease active site to prevent substrate access. In competitive inhibition, the inhibitor binds to the active site, thus preventing enzyme-substrate interaction. In non-competitive inhibition, the inhibitor binds to an allosteric site, which alters the active site and makes it inaccessible to the substrate. Examples of protease inhibitors include:
Henry's law states that the mole fraction of a dissolved gas (xg) is equal to the partial pressure of the gas (pg) at equilibrium divided by Henry's law constant (H). Gas solubility coefficients are used to calculate Henry's law constant:
=== Generic names === EMP is provided as the sodium salt for oral administration, which has the generic names estramustine phosphate sodium (USANTooltip United States Adopted Name) and estramustine sodium phosphate (BANMTooltip British Approved Name, JANTooltip Japanese Accepted Name), and as the meglumine salt for intravenous administration, which has the generic name estramustine phosphate meglumine. The INNMTooltip International Nonproprietary Name is estramustine phosphate. The name estramustine phosphate is a contraction of estradiol normustine phosphate. EMP is also known by its former developmental code names Leo 299, Ro 21-8837, and Ro 21-8837/001.
Sources: en.wikipedia.org
The HIV-1 PR precursor catalyzes its own production by facilitating its cleavage from the Gag-Pol polyprotein in a mechanism known as auto-processing. Auto-processing of HIV-1 PR is characterized by two sequential steps: (1) the intramolecular cleavage of the N-terminus at the p6pol-protease cleavage site, which serves to finalize PR processing and increase enzymatic activity with the newly formed PR-reverse transcriptase intermediate, and (2) the intermolecular cleavage of the C-terminus at the protease-reverse transcriptase cleavage site, leading to the assembly of two PR subunits into mature dimers. Dimerization of the two subunits allows for fully functional, combined active site, characterized by two Asp25 catalytic residues (one from each monomer), to form.
In January 1985, the sixth generation Familia/323 was fully renewed. It was available as a hatchback (with three or five doors) or four-door saloon only for the first year; wagon and cabriolet models were added in November 1985 and March 1986 respectively. The wagon was commonly sold as a light van in Japan, but for the first time it was also available as a passenger-oriented wagon model in the Japanese domestic market. In November 1986, cumulative production of Familias (excluding vans and pickups) reached five million units; at the time, Mazda was building about 40,000 Familia/323s per month. In January 1987 a personal coupé version with its own bodywork, the Étude, was added. In February 1987 the Familia range underwent a light facelift that included replacing the old E engines with the more modern B series. In some markets, such as Indonesia, the E engine continued to be installed after the facelift. This generation of the Familia/323 was also available in a version with a turbocharged DOHC engine, with either front- or four-wheel drive, producing 140 PS (103 kW). The 4WD version (sold in either a lightweight GT or fully optioned GT-X grade) introduced in October 1985, saw some success in rally's Group A category. A limited production Japanese-only homologation special, the 4WD GT-Ae, appeared May 1988 and offered an additional ten horsepower and viscous rear limited slip differential (similar to the later BG Familia). Full time four-wheel drive was also available in more pedestrian versions like the 1.5 hatchback.
In 2021, Schmitt led a lawsuit against the Biden administration challenging COVID-19 vaccine requirements for health care workers. In 2021, Schmitt challenged the administration's decision to suspend new oil and gas leases on federal land and water. In 2021, Schmitt and 13 other Republican state attorneys general sued to block an executive order directing federal agencies to consider the social costs of emissions of greenhouse gases (carbon, methane and nitrous oxide) in regulatory cost-benefit analyses. In 2021, Schmitt and 21 other Republican attorneys general sued the Biden administration over Biden's revocation of the permit for the Keystone XL Pipeline. In 2022, Schmitt and Jeff Landry of Louisiana sued the federal government, claiming it was censoring anti-vaccine activism on social media. In 2024, the Supreme Court in Murthy v. Missouri rejected the case due to the plaintiffs' lack of standing. In the decision, Justice Amy Coney Barrett found no evidence of government coercion and wrote that plaintiffs could not "manufacture standing" based on hypothetical or self-inflicted harm. In 2022, Schmitt and 21 other Republican state attorneys general sued the Biden administration over a program that prohibits discrimination based on sexual orientation and gender identity in schools that receive federal funds. In September 2022, Schmitt joined a lawsuit on behalf of the Higher Education Loan Authority of the State of Missouri to block the administration's executive order on student debt relief.
== Side effects == The adverse effects of 2C-B have been studied. They have been reported to include difficulty focusing gaze, trembling, sweating, nausea, abdominal pain, tachycardia, jaw clenching, difficulty breathing, coughing, diarrhea, dizziness, muscle or joint pain, tenseness, confusion, psychomotor slowing, and spatial memory impairment, among others. 2C-B produces much lower rates of fear and anxiety than other serotonergic psychedelics like psilocybin and LSD. Autonomic or sympathomimetic side effects include slightly increased heart rate and blood pressure and are lower than the increases with amphetamines and MDMA but similar to those with psilocybin. The drug produces a slight increase in cortisol levels that is also much lower than the marked increases observed with other psychedelics and MDMA. Hyperthermia has been reported at high doses. Residual side effects of 2C-B have been reported to include insomnia, flashbacks, anxiety, coughing, difficulty concentrating, and depression or sadness, among others. Severe adverse reactions are rare, but use of 2C-B was linked to significant brain injury in one case report; the alleged "2C-B" was never actually discovered by testing so the only evidence suggesting 2C-B was the cause was the victim's own words, without taking into consideration that adulteration and impurities are very common in illicit drugs. In a later case report of unknown dose, 2C-B caused serotonin syndrome, seizures, severe brain edema, and severe and long-lasting neurological impairment.
Sources: en.wikipedia.org
Naturally occurring gadolinium (64Gd) is composed of six stable isotopes, 154Gd, 155Gd, 156Gd, 157Gd, 158Gd and 160Gd, and one long-lived radioisotope, 152Gd, with 158Gd being the most abundant (24.84% natural abundance). The predicted double beta decay of 160Gd has not been observed. In all, 32 radioisotopes of gadolinium have been characterized, with the three most stable being alpha emitters: 152Gd (naturally occurring) with a half-life of 1.08×1014 years, 150Gd with a half-life of 1.79×106 years, and 148Gd (theoretically not beta-stable) with a half-life of 86.9 years. All of the remaining radioactive isotopes have half-lives less than a year, the majority of these having half-lives less than two minutes. There are also 16 metastable isomers, with the most stable being 143mGd (t1/2 = 110 seconds), 145mGd (t1/2 = 85 seconds) and 141mGd (t1/2 = 24.5 seconds). The isotopes with atomic masses lower than the most abundant stable isotope, 158Gd, primarily decay by electron capture to isotopes of europium. For higher atomic masses, the primary decay mode is beta decay to isotopes of terbium.
Patients starting morphine may experience nausea and vomiting (generally relieved by a short course of antiemetics such as phenergan). Pruritus (itching) may require switching to a different opioid. Constipation occurs in almost all patients on opioids, and laxatives (lactulose, macrogol-containing or co-danthramer) are typically co-prescribed. Opioid tolerance should not be confused with opioid-induced hyperalgesia. The symptoms of these two conditions can appear very similar but the mechanism of action is different. Opioid-induced hyperalgesia is when exposure to opioids increases the sensation of pain (hyperalgesia) and can even make non-painful stimuli painful (allodynia).
Democratic Left's theoretical foundation was rooted in the "New Times" intellectual movement that had emerged within Marxism Today during the 1980s. This movement, led by figures such as Martin Jacques, Stuart Hall, and Eric Hobsbawm, argued that the late 1980s represented a fundamental break with previous history, transitioning from Fordism to Post-Fordism. The "New Times" theorists contended that workers in western nations were no longer concentrated in large workplaces but were increasingly employed in the service and public sectors, requiring new political strategies beyond traditional class-based approaches. The influence of these ideas extended far beyond the Communist Party. Hobsbawm served as an advisor to Neil Kinnock, while many members of Blair's inner circle were former Eurocommunists influenced by the "New Times" school. Stuart Hall's analysis of Thatcherism - a term he pioneered - was cited by Labour Party figures in discussions about political strategy and messaging.
On July 2, 1992, John Crosbie, Canadian Federal Minister of Fisheries and Oceans, declared a two-year moratorium on the Northern Cod fishery, a designated fishing region off the coast of Newfoundland, after data showed that the total cod biomass had suffered a collapse to less than 1% of its normal value. The minister championed the measure as a temporary solution, allowing the cod population time to recover. The fisheries had long shaped the lives and communities on Canada's Atlantic eastern coast for the preceding five centuries. Societies which are dependent on fishing have a strong mutual relationship with them: the act of fishing changes the ecosystems' balance, which forces the fishery and, in turn, the fishing societies to adapt to new ecological conditions. The near-complete destruction of the Atlantic northwest cod biomass off the shores devastated coastal communities, which had been overexploiting the same cod population for decades. The fishermen along the Atlantic northwest had employed modern fishing technologies, including the ecologically devastating practice of trawling, especially in the years leading up to the 1990s, in the misguided belief that fishing stocks are perpetually plentiful and unable to be depleted. After this assumption was empirically and abruptly shown to be incorrect, to the dismay of government officials and rural workers, some 19,000 fishermen and cod processing plant workers in Newfoundland lost their employment.
== Plot == The story begins in a dark and gloomy rendition of Stockholm, with the protagonist Simon waking up in an alley after a car strikes him as he is trying to help an injured man. Simon tries to make his way home, but is attacked and chased by deformed monsters. After failing to call the police, Simon receives a text from a man pleading for help. When he enters and searches an apartment block, he finds the man dead in his bathtub. Progressing further, as the apartment building slowly grows more run-down (and eventually covered in blood), a chainsaw-wielding monster attacks him and decapitates itself upon defeat, prompting Simon to vomit and pass out. Simon wakes up near a cryptic and violent doctor who claims that he cannot trust him. After exploring the city and encountering more threats along the way, he finds Sophie, his childhood friend and love interest, on a rooftop. Simon attempts to confess his love to her, but she rejects his advances and commits suicide by jumping off the roof. A monster known as Carcass appears, giving Simon the choice to either kill it or flee from it back into the building. Simon continues on his journey home, attempting and failing to enter a subway station because he lacks a fuse. He goes to a nearby college to collect a fuse, however monsters ambush him upon finding it. Escaping to the station, Simon successfully enters where he, once again, encounters the doctor, murdering someone. Simon gives chase until his progress is blocked by a door needing two more fuses.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.